Drug Overview
Zulresso is SAGE Therapeutics’ proprietary intravenous formulation of brexanolone, which is an allosteric modulator of both synaptic and extra-synaptic GABA-A receptors. Zulresso was also investigated for super-refractory status epilepticus; however, it failed to meet the primary endpoint in its Phase III trial, hence its development for this indication was suspended.
The drug is a much-needed, novel prospect for post-partum depression (PPD) as there are currently no drugs approved for this indication. Impressively, Zulresso has produced potent, rapid-onset effects in PPD patients at 60 hours, and is a first-in-class drug addressing critical unmet need, spurring significant enthusiasm for the drug.
Analyst Outlook
Zulresso (intravenous brexanolone; SAGE Therapeutics) is a much-needed, novel prospect for post-partum depression (PPD) as there are currently no drugs approved for this indication. Impressively, Zulresso has produced potent, rapid-onset effects in PPD patients at 60 hours, and is a first-in-class drug addressing critical unmet need, spurring significant enthusiasm for the drug.
Zulresso is SAGE Therapeutics’ proprietary intravenous formulation of brexanolone, which is an allosteric modulator of both synaptic and extra-synaptic GABA-A receptors. Zulresso was also investigated for super-refractory status epilepticus; however, it failed to meet the primary endpoint in its Phase III trial, hence its development for this indication was suspended.
The drug is a much-needed, novel prospect for post-partum depression (PPD) as there are currently no drugs approved for this indication. Impressively, Zulresso has produced potent, rapid-onset effects in PPD patients at 60 hours, and is a first-in-class drug addressing critical unmet need, spurring significant enthusiasm for the drug.
Analyst Outlook
Zulresso (intravenous brexanolone; SAGE Therapeutics) is a much-needed, novel prospect for post-partum depression (PPD) as there are currently no drugs approved for this indication. Impressively, Zulresso has produced potent, rapid-onset effects in PPD patients at 60 hours, and is a first-in-class drug addressing critical unmet need, spurring significant enthusiasm for the drug.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
